Marina Magrey, ACR 2020 – Ixekizumab Response in Nr-axSpA Based on HLA-B27 and Disease Duration: The COAST-X Study

It was a pleasure to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about the recent post-hoc analysis from the COAST X study (NCT02757352). The analysis was designed to evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or without baseline HLA-B27 positivity and a disease duration of no more than 5 years. The abstract entitled ‘Response to Treatment with Ixekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis Based on HLA-B27 Status and Disease Duration’ was presented at ACR Convergence 2020, 5-9 November.

Questions

1. What is the rationale for the use of ixekizumab in the treatment of non-radiographic axial spondyloarthritis? Tell us about the COAST-X study and its findings, which led to ixekizumab’s approval in this indication. (0:06)
2. What were the aims of your recent post-hoc analysis of COAST-X data? (1:19)
3. What are the clinical implications of the findings of this analysis? (2:26)

Support:  Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of virtual ACR Convergence 2020.